What are you looking for? Write the name, title or any keyword related to what you are looking for and select which content category it belongs to. Search Fulltext search Activities Professionals Research groups News - Any - Professionals Fátima Sol Cabrera A Phase 2a, Open-label, Multicenter, Platform Trial to Assessthe Safety, Tolerability, and Efficacy of Inebilizumab andBlinatumomab in Subjects With Select Autoimmune Diseases Open Protocol code: 20240033 EudraCT code: No aplica Research group: Nephrology and kidney transplantation Service: Nephrology Principal investigator: Bestard Matamoros, Oriol Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase II Estudio clínico de fase 3, aleatorizado, controlado con placebo y doble ciego para evaluar la eficacia y la seguridad de molnupiravir (MK-4482) en adultos no hospitalizados con COVID-19 y alto riesgo de progresión de la enfermedad Open Protocol code: MK-4482-023 EudraCT code: No aplica Research group: Infectious Diseases Service: Infectious Principal investigator: Len Abad, Oscar Pathology: Certes malalties infeccioses i parasitàries Phase: Fase III Estudio de fase 1 del inhibidor de menina ziftomenib en combinación con quimioterapia en niños con leucemia aguda recidivante o resistente al tratamiento con reordenamientos de los genes KMT2A o NUP98, o con mutación en el gen NPM1 Open Protocol code: ITCC-101/APAL2020K EudraCT code: No aplica Research group: Childhood Cancer and Blood Disorders Service: Pediatric Oncohematology Principal investigator: Murillo Sanjuán , Laura Pathology: Tumors Phase: Fase I A Randomized, Double-masked, Multicenter, 3-Arm Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema Open Protocol code: EYE-RES-102 EudraCT code: No aplica Research group: Ophtalmology Service: Ophthalmology Principal investigator: Garrido Marin, Marta Pathology: Malalties de l’ull i dels seus annexos Phase: Fase III Status: Recruiting volunteers A phase 2a, multicenter, randomized, double-blind, placebo controlled study to evaluate the safety and pharmacodynamic effects of biib122 in participants with lrrk2-associated parkinson’s disease (lrrk2-pd) Open Protocol code: DNLI-C-0009 EudraCT code: _ Research group: Neurodegenerative Diseases Service: Neurology Principal investigator: Hernández Vara, Jorge Pathology: Malalties del sistema nerviós Phase: Fase II Status: Recruiting volunteers Letermovir (LMV) prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients with CMV seropositive donors: an exploratory study from Spanish GETH/TC Centers. Open Protocol code: TORMENT EudraCT code: No aplica Service: Hematology and Hematotherapy Principal investigator: Pérez González, Ana Pathology: Tumors Phase: Fase III Open-label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastroesophageal junction /gastric cancer.’ Open Protocol code: CL1-95029-002 EudraCT code: No aplica Research group: Biomedical Research in Digestive Tract Tumors Service: Oncology Principal investigator: Acosta Eyzaguirre, Daniel Pathology: Tumors Phase: Fase I Status: Recruiting volunteers Phase 3, Open-label, Uncontrolled Single-arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Avacopan in Combination With a Rituximab or a Cyclophosphamide-containing Regimen in Children from 6 Years to < 18 Years of Age with Active ANCA-associated Vasculitis (AAV) Open Protocol code: 20230070 EudraCT code: No aplica Research group: Kidney Physiopathology Service: Pediatric Nephrology Principal investigator: Ariceta Iraola, Gema Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase III Ensayo fase 2b, aleatorizado, doble ciego y controlado con placebo de búsqueda de rango de dosis para evaluar la eficacia y seguridad de múltiples dosis de AZD8630 inhalado administrado una vez al día durante 12 semanas en adultos con asma no controlada con riesgo de exacerbaciones (LEVANTE) Open Protocol code: D6830C00003 EudraCT code: No aplica Research group: Pneumology Service: Pneumology Principal investigator: Ojanguren Arranz, Iñigo Pathology: Malalties del sistema respiratori Phase: Fase II Status: Recruiting volunteers Estudio en fase 1/2 de determinación de la dosis y ampliación de la dosis de Cobolimab en combinación con Dostarlimab en participantes pediátricos y adultos jóvenes con tumores recién diagnosticados y recidivantes/resistentes al tratamiento Open Protocol code: 219451 EudraCT code: No aplica Research group: Childhood Cancer and Blood Disorders Service: Pediatric Oncohematology Principal investigator: Valero Arrese, Lorena Pathology: Tumors Phase: Fase I Status: Recruiting volunteers PROLONGACIÓN DEL BESTOW: Estudio en fase II, multicéntrico, sinenmascaramiento y de prolongación para evaluar la seguridad y eficacia a largo plazo de tegoprubarten receptores de trasplante de riñón Open Protocol code: AT-1501-K209 EudraCT code: No aplica Research group: Nephrology and kidney transplantation Service: Nephrology Principal investigator: Bestard Matamoros, Oriol Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase II Status: Recruiting volunteers ENSAYO EN FASE Ib EN CANASTA SIN ENMASCARAMIENTO DE RAY121 PARA INHIBIR LA VÍA CLÁSICA DEL COMPLEMENTO EN ENFERMEDADES INMUNOLÓGICAS Open Protocol code: RAY902CT EudraCT code: No aplica Research group: Systemic Diseases Service: Internal Medicine Principal investigator: Pardos Gea, José Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase I Optimization of albuminuria lowering therapies to individual patients with CKD using FINErenone and SEmaglutide. Open Protocol code: 17456 (FINESSE) EudraCT code: _ Research group: Nephrology and kidney transplantation Service: Nephrology Principal investigator: Soler Romeo, Maria Jose Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase II Status: Recruiting volunteers Un ensayo multicéntrico, aleatorizado y doble ciego para evaluar laeficacia y la seguridad de PRAX-628 en adultos con crisis focales (POWER 1) Open Protocol code: PRAX-628-321 EudraCT code: No aplica Research group: Research Group on Status Epilepticus and Acute Seizures Service: Neurology Principal investigator: Toledo Argany, Manuel Pathology: Tumors Phase: Fase I ESTUDIO EN FASE IB MULTICÉNTRICO, NO ALEATORIZADO,ABIERTO, ADAPTATIVO, CON GRUPOS PARALELOS, DE DOSIS ÚNICAS ASCENDENTES(PARTES 1 Y 2) Y DOSIS MÚLTIPLES ASCENDENTES (PARTE 3) PARA INVESTIGAR LASEGURIDAD, TOLERABILIDAD, INMUNOGENICIDAD, FARMACOCINÉTICA YFARMACODINAMIA DE RO7121932 TRAS ADMINISTRACIÓN POR VÍA INTRAVENOSA(PARTE 1) Y SUBCUTÁNEA (PARTES 2 Y 3) EN PARTICIPANTES CON ESCLEROSISMÚLTIPLE Open Protocol code: BP42230 EudraCT code: 2020-004122-33 Research group: Clinical Neuroimmunology Service: Neuroimmunology Principal investigator: Montalban Gairín, Xavier Pathology: Malalties del sistema nerviós Phase: Fase I Status: Recruiting volunteers An open label complex clinical trial in newly diagnosed pediatric de novo AML patients – a study by the NOPHO-DB-SHIP consortium Open Protocol code: CHIP-AML22/Master EudraCT code: No aplica Research group: Childhood Cancer and Blood Disorders Service: Pediatric Oncohematology Principal investigator: Murillo Sanjuán , Laura Pathology: Tumors Phase: Fase III Status: Recruiting volunteers Estudio Fase 2b, multicéntrico, aleatorizado, parcialmentecontrolado con placebo y doble ciego para evaluar la seguridad y eficacia de laadministración secuencial de Daplusiran/Tomligisiran seguido de bepirovirsen enparticipantes con Hepatitis B crónica en tratamiento con análogos de nucleós(t)idos (BUnited). Open Protocol code: 218309 EudraCT code: No aplica Research group: Liver Diseases Service: Hepatology Principal investigator: Buti Ferret, Maria Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase II Status: Recruiting volunteers Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y degrupos paralelos para evaluar la eficacia y la seguridad de dapirolizumab pegol en participantes del estudio con lupus eritematoso sistémico de moderado a grave Open Protocol code: SL0044 EudraCT code: 2019-003407-35 Research group: Rheumatology Service: Rheumatology Principal investigator: Cortes Hernandez, Josefina Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més Phase: Fase III A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients with Multiple System Atrophy Open Protocol code: TV56286-NDG-20039 EudraCT code: No aplica Research group: Neurodegenerative Diseases Service: Neurology Principal investigator: Hernández Vara, Jorge Pathology: Malalties del sistema nerviós Phase: Fase II Pagination First page « Previous page ‹ … Page 1394 Page 1395 Current page 1396 Page 1397 Page 1398 … Next page › Last page »
